Great analysis of DLL3 expression in SCLC and difficult to treat neuroendocrine neoplasms. Excited to see more biomarker driven approaches to advance care in such needed spaces.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms - npj Precision Oncology
npj Precision Oncology - Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
www.nature.com
November 20, 2024 at 1:00 AM
Great analysis of DLL3 expression in SCLC and difficult to treat neuroendocrine neoplasms. Excited to see more biomarker driven approaches to advance care in such needed spaces.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Important poster presented at #TTLC25 by @jessieross.bsky.social and Alissa Cooper from @mskcancercenter.bsky.social on overlap of DLL3/SEZ6 in high grade neuroendocrine cancers
February 22, 2025 at 5:17 PM
Important poster presented at #TTLC25 by @jessieross.bsky.social and Alissa Cooper from @mskcancercenter.bsky.social on overlap of DLL3/SEZ6 in high grade neuroendocrine cancers
Small-cell lung cancer that relapses after platinum chemotherapy has few effective treatment options. The DeLLphi-304 phase 3 trial shows improved survival and symptom control with the DLL3-targeted T-cell engager tarlatamab. nej.md/4kWVuyB
#MedSky #Oncology
#MedSky #Oncology
July 26, 2025 at 7:00 PM
Small-cell lung cancer that relapses after platinum chemotherapy has few effective treatment options. The DeLLphi-304 phase 3 trial shows improved survival and symptom control with the DLL3-targeted T-cell engager tarlatamab. nej.md/4kWVuyB
#MedSky #Oncology
#MedSky #Oncology
New Pete Buttigieg interview dropped.
www.youtube.com/watch?v=DlL3...
www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 1, 2025 at 9:42 PM
New Pete Buttigieg interview dropped.
www.youtube.com/watch?v=DlL3...
www.youtube.com/watch?v=DlL3...
Agree that this dll3 targeted therapies are changing this landscape. We need to improve the logistics of how they are delivered to make it more accesible
Great analysis of DLL3 expression in SCLC and difficult to treat neuroendocrine neoplasms. Excited to see more biomarker driven approaches to advance care in such needed spaces.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms - npj Precision Oncology
npj Precision Oncology - Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
www.nature.com
November 20, 2024 at 4:09 PM
Agree that this dll3 targeted therapies are changing this landscape. We need to improve the logistics of how they are delivered to make it more accesible
Promising Activity in DLL3-Positive SCLC and NECs with a Novel Bispecific T-Cell Engager
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SCLC #NECs #LungCancer #NETs
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SCLC #NECs #LungCancer #NETs
Promising Activity in DLL3-Positive SCLC and NECs with a Novel Bispecific T-Cell Engager - OncoDaily
Promising activity and manageable safety shown by a novel bispecific T-cell engager in advanced DLL3-positive SCLC and NECs.
oncodaily.com
July 31, 2025 at 9:56 PM
Promising Activity in DLL3-Positive SCLC and NECs with a Novel Bispecific T-Cell Engager
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SCLC #NECs #LungCancer #NETs
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SCLC #NECs #LungCancer #NETs
Following the FDA’s approval of Amgen’s pioneering DLL3 × CD3 bispecific antibody tarlatamab last year, Ideaya and Roche have now both stuck deals for DLL3-targeted antibody-drug conjugates, highlighting the race to pursue this target nature.com/articles/d41...
January 13, 2025 at 4:14 PM
Following the FDA’s approval of Amgen’s pioneering DLL3 × CD3 bispecific antibody tarlatamab last year, Ideaya and Roche have now both stuck deals for DLL3-targeted antibody-drug conjugates, highlighting the race to pursue this target nature.com/articles/d41...
DLL3 Expression in EGFR NSCLC after SCLC Transformation - Stephen V Liu
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DLL3 #NSCLC #SCLC #LungCancer
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DLL3 #NSCLC #SCLC #LungCancer
Stephen V Liu: DLL3 Expression in EGFR NSCLC after SCLC Transformation - OncoDaily
Stephen V Liu: DLL3 Expression in EGFR NSCLC after SCLC Transformation / cancer, Carlos J. Suarez, Farshad Moradi, Gerald J. Berry, Heather A. Wakelee,
oncodaily.com
October 4, 2025 at 8:07 PM
DLL3 Expression in EGFR NSCLC after SCLC Transformation - Stephen V Liu
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DLL3 #NSCLC #SCLC #LungCancer
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DLL3 #NSCLC #SCLC #LungCancer
youtube.com/watch?v=DlL3...
Nice PETE BUTTIGIEG
interview. Nice listen.
#petebuttigieg #ericswalwell #politics #news #peoole#dc #newyork #lgbtq
Nice PETE BUTTIGIEG
interview. Nice listen.
#petebuttigieg #ericswalwell #politics #news #peoole#dc #newyork #lgbtq
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
youtube.com
October 2, 2025 at 1:58 AM
youtube.com/watch?v=DlL3...
Nice PETE BUTTIGIEG
interview. Nice listen.
#petebuttigieg #ericswalwell #politics #news #peoole#dc #newyork #lgbtq
Nice PETE BUTTIGIEG
interview. Nice listen.
#petebuttigieg #ericswalwell #politics #news #peoole#dc #newyork #lgbtq
Pete Buttigieg Interview.
www.youtube.com/watch?v=DlL3...
www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 1, 2025 at 7:07 PM
Pete Buttigieg Interview.
www.youtube.com/watch?v=DlL3...
www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 1, 2025 at 10:15 PM
COOL! Prof #Renier_Brentjens @roswellpark.bsky.social #Cancer #Center/ #CAR_T #immunotherapy to #DLL3 using scFvs /SC16.8 cures #SCLC in mice without #lymphodepletion #Bridge2024 @sitcancer.bsky.social @egfrpositiveuk.bsky.social @alkpositiveuk.bsky.social @cruk-mi.bsky.social #SmallCellLungCancer
December 4, 2024 at 9:50 AM
COOL! Prof #Renier_Brentjens @roswellpark.bsky.social #Cancer #Center/ #CAR_T #immunotherapy to #DLL3 using scFvs /SC16.8 cures #SCLC in mice without #lymphodepletion #Bridge2024 @sitcancer.bsky.social @egfrpositiveuk.bsky.social @alkpositiveuk.bsky.social @cruk-mi.bsky.social #SmallCellLungCancer
DLL3 expression in high-grade NENs? Not rare at all! Check out this large study. 64% of NECs pos, 42% lung NETs, but only 5% GEPNETs are pos with the exception of G3 NETs which are 20% mod or strongly pos. DLL3-directed trials coming but not for G3 NETs.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms - Endocrine Pathology
Delta-like ligand 3 (DLL3) is frequently expressed in pulmonary small cell neuroendocrine carcinoma (SCNEC) and has emerged as a promising therapeutic target. However, limited data on DLL3 expression ...
link.springer.com
March 30, 2025 at 3:45 PM
DLL3 expression in high-grade NENs? Not rare at all! Check out this large study. 64% of NECs pos, 42% lung NETs, but only 5% GEPNETs are pos with the exception of G3 NETs which are 20% mod or strongly pos. DLL3-directed trials coming but not for G3 NETs.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Innovent is receiving $80m up front in a deal with Roche for a DLL3-targeting ADC. The deal comes just a few days after Ideaya and Hengrui forged another east-west partnership around a DLL3 ADC. www.prnewswire.com/news-release...
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
www.prnewswire.com
January 2, 2025 at 12:35 PM
Innovent is receiving $80m up front in a deal with Roche for a DLL3-targeting ADC. The deal comes just a few days after Ideaya and Hengrui forged another east-west partnership around a DLL3 ADC. www.prnewswire.com/news-release...
DLL3 downregulation could be the expected mechanism of resistance to the tarlatamab BiTE in SCLC. This small study shows SCLC subtype switching, suggesting that intra-tumoral heterogeneity with pre-existing DLL3-low ASCL1-neg SCLC cells is an “easier” mechanism? Interesting! tinyurl.com/ye29dx6v
January 4, 2025 at 1:25 AM
DLL3 downregulation could be the expected mechanism of resistance to the tarlatamab BiTE in SCLC. This small study shows SCLC subtype switching, suggesting that intra-tumoral heterogeneity with pre-existing DLL3-low ASCL1-neg SCLC cells is an “easier” mechanism? Interesting! tinyurl.com/ye29dx6v
🌟No1: DLL3/T-cell Engagers (Tarlatamab/ Obrixtamig)
Those agents engage neuroendocrine cells expressing DLL3 to T-lymphocytes via TCR binding. Breakthrough FDA approval based on phase 2 data, including impressive ORR of 40% and mOS of 14.2 m. Phase 3 results vs SoC highly anticipated in 2025
Those agents engage neuroendocrine cells expressing DLL3 to T-lymphocytes via TCR binding. Breakthrough FDA approval based on phase 2 data, including impressive ORR of 40% and mOS of 14.2 m. Phase 3 results vs SoC highly anticipated in 2025
December 28, 2024 at 11:26 AM
🌟No1: DLL3/T-cell Engagers (Tarlatamab/ Obrixtamig)
Those agents engage neuroendocrine cells expressing DLL3 to T-lymphocytes via TCR binding. Breakthrough FDA approval based on phase 2 data, including impressive ORR of 40% and mOS of 14.2 m. Phase 3 results vs SoC highly anticipated in 2025
Those agents engage neuroendocrine cells expressing DLL3 to T-lymphocytes via TCR binding. Breakthrough FDA approval based on phase 2 data, including impressive ORR of 40% and mOS of 14.2 m. Phase 3 results vs SoC highly anticipated in 2025
Finally, great story re: evolution of bispecific T cell enagager (BiTE) - Dr Martijn Lolkema @amgen.bsky.social.
A journey re:
• Blinatumomab, CD19
• Tarlatamab, DLL3
• Tebentafusp, gp100
• Xaluritamig, STEAP1
etc
To navigate current challenges, more innovative technologies emerging! 🚀 #ESMOTAT25
A journey re:
• Blinatumomab, CD19
• Tarlatamab, DLL3
• Tebentafusp, gp100
• Xaluritamig, STEAP1
etc
To navigate current challenges, more innovative technologies emerging! 🚀 #ESMOTAT25
March 4, 2025 at 9:07 AM
Finally, great story re: evolution of bispecific T cell enagager (BiTE) - Dr Martijn Lolkema @amgen.bsky.social.
A journey re:
• Blinatumomab, CD19
• Tarlatamab, DLL3
• Tebentafusp, gp100
• Xaluritamig, STEAP1
etc
To navigate current challenges, more innovative technologies emerging! 🚀 #ESMOTAT25
A journey re:
• Blinatumomab, CD19
• Tarlatamab, DLL3
• Tebentafusp, gp100
• Xaluritamig, STEAP1
etc
To navigate current challenges, more innovative technologies emerging! 🚀 #ESMOTAT25
Marker-based CRISPR screens identify POU2F1 as a regulator of DLL3 and neuroendocrine identity in small cell lung cancer https://www.biorxiv.org/content/10.64898/2026.04.08.717069v1
April 10, 2026 at 1:50 PM
Marker-based CRISPR screens identify POU2F1 as a regulator of DLL3 and neuroendocrine identity in small cell lung cancer https://www.biorxiv.org/content/10.64898/2026.04.08.717069v1
target prosecution like this bispecific is a delicate dance between hoped-for efficacy and avoided toxicity ... the EGFRxHER3 pair is a good choice. Why? see here ... sugarconebiotech.com/insights/tar...
Targeting HER3 – a little wave of drug development that’s about to get a lot bigger — SugarCone Biotech
A post-ASCO update on tumor targets DLL3, B7H3 and HER3 July 2025 Paul D Rennert, SugarCone Biotech LLC Introduction: DLL3, B7H3 and HER3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse t
sugarconebiotech.com
August 15, 2025 at 6:04 PM
target prosecution like this bispecific is a delicate dance between hoped-for efficacy and avoided toxicity ... the EGFRxHER3 pair is a good choice. Why? see here ... sugarconebiotech.com/insights/tar...
DLL3 Expression in Neuroendocrine Neoplasms - an overview ronnyallan.net/2025/06/27/d...
DLL3 Expression in Neuroendocrine Neoplasms - an overview Ronny Allan - Living with Neuroendocrine Cancer
Treatment
ronnyallan.net
March 26, 2026 at 1:22 PM
DLL3 Expression in Neuroendocrine Neoplasms - an overview ronnyallan.net/2025/06/27/d...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 2, 2025 at 12:59 AM
An investigational DLL3-targeting antibody-drug conjugate, ZL-1310, showed safety and anticancer responses in patients with extensive-stage small cell lung cancer. Grace K. Dy, MD, of @roswellpark.bsky.social presented phase I clinical trial results at #Targets25. buff.ly/iZCWaXU
October 25, 2025 at 1:33 AM
An investigational DLL3-targeting antibody-drug conjugate, ZL-1310, showed safety and anticancer responses in patients with extensive-stage small cell lung cancer. Grace K. Dy, MD, of @roswellpark.bsky.social presented phase I clinical trial results at #Targets25. buff.ly/iZCWaXU
FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL1310 in ES-SCLC #lcsm #oncology www.onclive.com/view/fda-gra...
FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL1310 in ES-SCLC
The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.
www.onclive.com
May 19, 2025 at 2:51 PM
FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL1310 in ES-SCLC #lcsm #oncology www.onclive.com/view/fda-gra...
Now online in Cancer Discovery AACR Journals: CTCs Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab - by Avanish Mishra, Catherine Meador, Kruthika Kikkeri, Shyamala Maheswaran, Justin Gainor, Daniel Haber, et al. doi.org/10.1158/2159... @mgbresearch.bsky.social
January 15, 2026 at 9:00 PM
Now online in Cancer Discovery AACR Journals: CTCs Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab - by Avanish Mishra, Catherine Meador, Kruthika Kikkeri, Shyamala Maheswaran, Justin Gainor, Daniel Haber, et al. doi.org/10.1158/2159... @mgbresearch.bsky.social
For fans of SNL - in Stefon's words: this paper "has everything". If you are interested in pathology or biology of carcinoids/NETs, lung vs GI/pancreas, DLL3 etc - this paper has something for you! Please check it out.
January 6, 2026 at 4:46 AM
For fans of SNL - in Stefon's words: this paper "has everything". If you are interested in pathology or biology of carcinoids/NETs, lung vs GI/pancreas, DLL3 etc - this paper has something for you! Please check it out.